Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19026966 | NOVEL AAV CAPSIDS FOR TARGETING NERVOUS SYSTEM AND USES THEREOF | January 2025 | August 2025 | Allow | 7 | 1 | 0 | Yes | No |
| 18990401 | COMPOSITION FOR REGULATING PRODUCTION OF PROTEINS | December 2024 | March 2025 | Allow | 3 | 0 | 0 | No | No |
| 18717225 | MUTANT MYOCILIN DISEASE MODEL AND USES THEREOF | June 2024 | December 2025 | Allow | 18 | 1 | 1 | Yes | No |
| 17925109 | TREATMENT OF COMPLICATIONS CAUSED BY INFECTIONS OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS | November 2022 | March 2026 | Abandon | 40 | 0 | 1 | No | No |
| 18046740 | Self-Complementary Adeno-Associated Virus Vector and its Use in Treatment of Muscular Dystrophy | October 2022 | July 2024 | Allow | 21 | 1 | 1 | No | No |
| 17938545 | METHODS AND COMPOSITIONS FOR ENHANCING ACTIVITY OF T CELLS WITH MODIFIED B CELLS | October 2022 | February 2026 | Abandon | 40 | 0 | 1 | No | No |
| 17931858 | GENE EDITING TOOLS | September 2022 | February 2026 | Allow | 41 | 1 | 1 | No | No |
| 17895418 | METHOD FOR ISOLATING AND PURIFYING MESENCHYMAL STEM CELLS FROM HERNIA SAC AND METHOD FOR TISSUE REPAIR BY USING MESENCHYMAL STEM CELLS FROM HERNIA SAC | August 2022 | June 2025 | Abandon | 33 | 3 | 1 | Yes | No |
| 17886407 | INDUCTION OF NEUROGENESIS USING UMBILICAL CORD DERIVED MESENCHYMAL STEM CELLS AND DERIVATIVES THEREOF | August 2022 | May 2024 | Abandon | 22 | 0 | 1 | No | No |
| 17819052 | USE OF MESENCHYMAL STEM CELLS AND COMPOSITIONS CONTAINING THEM IN THE MANUFACTURE OF A MEDICAMENT FOR TREATING HARD-TO-HEAL BURN WOUNDS | August 2022 | May 2025 | Abandon | 33 | 3 | 1 | No | No |
| 17770138 | AAV3B VARIANTS WITH IMPROVED PRODUCTION YIELD AND LIVER TROPISM | April 2022 | November 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17630883 | T CELL PRODUCTION FROM RAG INACTIVATED IPSCS | January 2022 | December 2025 | Abandon | 46 | 0 | 1 | No | No |
| 17603831 | COMPOSITIONS AND METHODS FOR TREATMENT OF CYSTIC FIBROSIS | October 2021 | June 2025 | Abandon | 44 | 1 | 1 | No | No |
| 17500426 | REAGENTS AND METHODS FOR MODULATING CONE PHOTORECEPTOR ACTIVITY | October 2021 | May 2025 | Allow | 43 | 0 | 1 | No | No |
| 17601406 | Engineered System of Stem Cell Rejuvenation to Treat Aging and Disease | October 2021 | July 2025 | Abandon | 46 | 0 | 1 | No | No |
| 17491757 | MATERIALS AND METHODS FOR ENGINEERING CELLS AND USES THEREOF IN IMMUNO-ONCOLOGY | October 2021 | July 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17599431 | METHODS, COMPOSITIONS, AND KITS FOR PRODUCING SKELETAL MUSCLE STEM CELLS AND TREATING DISORDERS | September 2021 | November 2025 | Abandon | 49 | 1 | 1 | No | No |
| 17593285 | PRODUCTION OF LARGE-SIZED QUASIDYSTROPHINS USING OVERLAPPING AAV VECTORS | September 2021 | July 2025 | Allow | 46 | 1 | 1 | No | No |
| 17437172 | NON-VIRAL DNA VECTORS AND USES THEREOF FOR EXPRESSING PHENYLALANINE HYDROXYLASE (PAH) THERAPEUTICS | September 2021 | May 2025 | Allow | 44 | 1 | 1 | Yes | No |
| 17435235 | INDUCED PHOTORECEPTOR CELLS AND METHODS FOR THEIR PRODUCTION | August 2021 | June 2025 | Allow | 46 | 1 | 1 | Yes | No |
| 17434284 | COMPOSITIONS AND METHODS FOR LONG TERM CULTURE OF HEPATOCYTES | August 2021 | October 2025 | Allow | 50 | 2 | 1 | Yes | No |
| 17433713 | METHOD AND COMPOSITION FOR TREATING GASTROINTESTINAL INFLAMMATORY DISORDERS | August 2021 | September 2025 | Allow | 49 | 3 | 0 | No | Yes |
| 17429996 | REVERSE IMMUNOSUPPRESSION | August 2021 | May 2025 | Abandon | 45 | 2 | 0 | Yes | No |
| 17430269 | DUAL LEUCINE ZIPPER KINASE INHIBITORS FOR GENE THERAPY | August 2021 | January 2025 | Allow | 41 | 2 | 0 | No | No |
| 17430020 | METHOD FOR PREPARING MATURE RED BLOOD CELLS IN VITRO USING PERIPHERAL BLOOD | August 2021 | July 2025 | Allow | 48 | 2 | 0 | No | No |
| 17427551 | Inducible AAV System Comprising Cumate Operator Sequences | July 2021 | May 2025 | Allow | 45 | 2 | 0 | No | No |
| 17425935 | CELL POPULATIONS WITH IMPROVED PRODUCTION AND THERAPEUTIC CHARACTERISTICS | July 2021 | January 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17423693 | LIVER-SPECIFIC INDUCIBLE PROMOTERS AND METHODS OF USE THEREOF | July 2021 | July 2025 | Allow | 48 | 1 | 1 | No | No |
| 17375808 | COMPOSITIONS AND METHODS OF USE FOR SMALL-MOLECULE REGULATION OF CRISPR-CAS9 ACTIVITY USING RNA APTAMERS | July 2021 | May 2025 | Allow | 46 | 2 | 1 | No | No |
| 17417131 | CHARACTERIZATION AND INACTIVATION OF ENDOGENOUS RETROVIRUSES IN CHINESE HAMSTER OVARY CELLS | June 2021 | April 2025 | Allow | 46 | 1 | 1 | Yes | No |
| 17417123 | ACINETOBACTER BAUMANNII BACTERIOPHAGE MIKAB48 OR LYTIC PROTEIN DERIVED FROM THE BACTERIOPHAGE | June 2021 | December 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17416559 | OPTIMIZED GALC GENES AND EXPRESSION CASSETTES AND THEIR USE | June 2021 | March 2025 | Allow | 45 | 1 | 1 | Yes | No |
| 17416601 | METHODS AND MATERIALS FOR SINGLE CELL TRANSCRIPTOME-BASED DEVELOPMENT OF AAV VECTORS AND PROMOTERS | June 2021 | October 2025 | Abandon | 51 | 2 | 1 | No | No |
| 17413314 | IMMUNOMODULATORY CELLS AND USES THEREOF | June 2021 | January 2026 | Allow | 56 | 3 | 1 | Yes | No |
| 17312755 | CELL | June 2021 | December 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17312808 | CRISPR GENE THERAPY OF FUSION GENE RELATED CANCERS | June 2021 | August 2024 | Allow | 38 | 1 | 0 | No | No |
| 17341244 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING USHER SYNDROME AND RETINITIS PIGMENTOSA | June 2021 | October 2025 | Allow | 52 | 1 | 2 | No | No |
| 17299542 | VECTORS FOR PROTEIN MANUFACTURE | June 2021 | July 2024 | Allow | 38 | 1 | 0 | Yes | No |
| 17320758 | LIVER-SPECIFIC VIRAL PROMOTERS AND METHODS OF USING THE SAME | May 2021 | February 2025 | Allow | 45 | 1 | 2 | Yes | No |
| 17293568 | CRY2 VARIANT HAVING INCREASED PHOTOSENSITIVITY AND USE THEREOF | May 2021 | July 2024 | Allow | 38 | 1 | 0 | No | No |
| 17292357 | RECOMBINANT VECTORS COMPRISING GENES FOR BINDING DOMAINS AND SECRETABLE PEPTIDES | May 2021 | November 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17288311 | COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED MACULAR DEGENERATION AND OTHER DISEASES | April 2021 | November 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17287379 | SYNP27 (PROB12), A PROMOTER FOR THE SPECIFIC EXPRESSION OF GENES IN PROTOPLASMIC ASTROCYTES | April 2021 | October 2024 | Abandon | 42 | 1 | 0 | No | No |
| 17284043 | Selective Curbing of Unwanted RNA Editing (SECURE) DNA Base Editor Variants | April 2021 | December 2025 | Allow | 57 | 4 | 0 | Yes | No |
| 17284145 | COMPOSITION AND METHOD FOR INHIBITING TAU PROTEIN ACCUMULATION, AGGREGATION, AND TANGLE FORMATION | April 2021 | November 2025 | Allow | 55 | 4 | 0 | Yes | No |
| 17284169 | Oncolytic Vaccinia Virus With Modified B5R Gene For The Treatment Of Cancer | April 2021 | August 2025 | Allow | 53 | 3 | 1 | Yes | No |
| 17222910 | CHIMERIC NUCLEIC ACID MOLECULES WITH NON-AUG TRANSLATION INITIATION SEQUENCES AND USES THEREOF | April 2021 | September 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17222851 | SYSTEMS AND METHODS FOR COMPARTMENT SPATIAL ORGANIZATION | April 2021 | August 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17276186 | DESIGN OF ALCOHOL DEHYDROGENASE 2 (ADH2) PROMOTER VARIANTS BY PROMOTER ENGINEERING | March 2021 | June 2024 | Allow | 39 | 1 | 0 | No | No |
| 17200574 | COMPOSITIONS AND METHODS FOR EXCISION WITH SINGLE GRNA | March 2021 | July 2025 | Abandon | 52 | 2 | 0 | No | No |
| 17275169 | ORGANOID COMPOSITIONS FOR THE PRODUCTION OF HEMATOPOIETIC STEM CELLS AND DERIVATIVES THEREOF | March 2021 | June 2025 | Allow | 51 | 3 | 1 | Yes | No |
| 17272172 | PROGRAMMED CELL DEATH 1 (PD1) SPECIFIC NUCLEASES | February 2021 | September 2024 | Abandon | 42 | 1 | 0 | No | No |
| 17272018 | DIRECTED PSEUDOURIDYLATION OF RNA | February 2021 | November 2024 | Abandon | 45 | 1 | 0 | No | No |
| 17180535 | SYSTEMS AND METHODS FOR POLYNUCLEOTIDE SPATIAL ORGANIZATION | February 2021 | October 2024 | Abandon | 43 | 1 | 1 | No | No |
| 17266528 | PROMOTER of Hspa8 GENE | February 2021 | August 2024 | Abandon | 42 | 1 | 0 | No | No |
| 17262789 | IN VIVO DELIVERY SYSTEM OF THE GENOME DNA MODIFYING ENZYMES AND THE USE THEREOF | January 2021 | June 2025 | Abandon | 53 | 3 | 1 | Yes | No |
| 17259165 | VESICLES FOR TRACELESS DELIVERY OF GUIDE RNA MOLECULES AND/OR GUIDE RNA MOLECULE/RNA-GUIDED NUCLEASE COMPLEX(ES) AND A PRODUCTION METHOD THEREOF | January 2021 | October 2024 | Abandon | 45 | 1 | 1 | No | No |
| 17059193 | GENE EDITING OF MONOGENIC DISORDERS IN HUMAN HEMATOPOIETIC STEM CELLS -- CORRECTION OF X-LINKED AGAMMAGLOBULINEMIA (XLA) | November 2020 | August 2025 | Allow | 56 | 1 | 1 | No | No |
| 17058381 | COMPOSITIONS AND METHODS FOR IMMUNOONCOLOGY | November 2020 | October 2024 | Abandon | 47 | 0 | 1 | No | No |
| 17050145 | PHARMACEUTICAL KIT AND USES THEREOF | October 2020 | February 2025 | Abandon | 52 | 1 | 0 | No | No |
| 17048928 | CHIMERIC ANTIGEN RECEPTOR AND CAR-T CELLS THAT BIND A HERPES VIRUS ANTIGEN | October 2020 | March 2024 | Allow | 41 | 1 | 0 | No | No |
| 17045087 | VIRUS VECTORS FOR TARGETING OPHTHALMIC TISSUES | October 2020 | June 2024 | Allow | 44 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SMALL, KATHERINE R.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner SMALL, KATHERINE R works in Art Unit 1633 and has examined 50 patent applications in our dataset. With an allowance rate of 54.0%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 45 months.
Examiner SMALL, KATHERINE R's allowance rate of 54.0% places them in the 15% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by SMALL, KATHERINE R receive 1.30 office actions before reaching final disposition. This places the examiner in the 18% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by SMALL, KATHERINE R is 45 months. This places the examiner in the 12% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +44.0% benefit to allowance rate for applications examined by SMALL, KATHERINE R. This interview benefit is in the 90% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 35.0% of applications are subsequently allowed. This success rate is in the 78% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 40.0% of cases where such amendments are filed. This entry rate is in the 61% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 86% percentile among all examiners. Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 40.0% are granted (fully or in part). This grant rate is in the 29% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.